Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration

被引:28
|
作者
Patel, Y. A. [1 ]
Gifford, E. J. [1 ]
Glass, L. M. [1 ]
McNeil, R. [1 ]
Turner, M. J. [1 ]
Han, B. [1 ]
Provenzale, D. [1 ]
Choi, S. S. [1 ]
Moylan, C. A. [1 ]
Hunt, C. M. [1 ]
机构
[1] Duke Univ, Hosp South, Durham, NC 27708 USA
关键词
UNITED-STATES; HEPATOCELLULAR-CARCINOMA; NONINVASIVE DIAGNOSIS; HISTOLOGICAL SEVERITY; BARIATRIC SURGERY; ADVANCED FIBROSIS; NAFLD FIBROSIS; STEATOHEPATITIS; METAANALYSIS; PROGRESSION;
D O I
10.1111/apt.14411
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: With its increasing incidence, nonalcoholic fatty liver disease (NAFLD) is of particular concern in the Veterans Health Administration (VHA). Aims: To evaluate risk factors for advanced fibrosis in biopsy-proven NAFLD in the VHA, to identify patients at risk for adverse outcomes. Methods: In randomly selected cases from VHA databases (2005-2015), we performed a retrospective case-control study in adults with biopsy-defined NAFLD or normal liver. Results: Of 2091 patients reviewed, 399 met inclusion criteria. Normal controls (n = 65) had normal liver function. The four NAFLD cohorts included: NAFL steatosis (n = 76), nonalcoholic steatohepatitis (NASH) without fibrosis (n = 68), NAFLD/NASH stage 1-3 fibrosis (n = 82), and NAFLD/NASH cirrhosis (n = 70). NAFLD with hepatocellular carcinoma (HCC) was separately identified (n = 38). Most patients were older White men. NAFLD patients with any fibrosis were on average severely obese (BMI>35 kg/m(2)). Diabetes (54.4%-79.6%) and hypertension (85.8%-100%) were more common in NAFLD with fibrosis or HCC. Across NAFLD, 12.3%-19.5% were enrolled in diet/exercise programs and 0%-2.6% had bariatric surgery. Hispanics exhibited higher rates of NASH (20.6%), while Blacks had low NAFLD rates (1.4%-11.8%), particularly NAFLD cirrhosis and HCC (1.4%-2.6%). Diabetes (OR 11.8, P < .001) and BMI (OR 1.4, P < .001) were the most significant predictors of advanced fibrosis. Conclusions: In the VHA, diabetes and severe obesity increased risk for advanced fibrosis in NAFLD. Of these patients, only a small proportion (similar to 20%) had enrolled in diet/exercise programs or had bariatric surgery (similar to 2%). These results suggest that providers should focus/tailor interventions to improve outcomes, particularly in those with diabetes and severe obesity.
引用
收藏
页码:268 / 278
页数:11
相关论文
共 50 条
  • [21] Factors Associated with Deep Vein Thrombosis in Type 2 Diabetics with Biopsy-Proven Non-alcoholic Fatty Liver Disease
    Amandeep Singh
    Aly ElBoraie
    Nan Lan
    Mohit Gupta
    SN Comprehensive Clinical Medicine, 2020, 2 (1) : 32 - 41
  • [22] Association of the serum uric acid level with liver histology in biopsy-proven non-alcoholic fatty liver disease
    Huang, Qian
    Yu, Jianhua
    Zhang, Xiantu
    Liu, Shourong
    Ge, Yanyan
    BIOMEDICAL REPORTS, 2016, 5 (02) : 188 - 192
  • [23] Association of homocysteine level with biopsy-proven non-alcoholic fatty liver disease: a meta-analysis
    Dai, Yining
    Zhu, Jinzhou
    Meng, Di
    Yu, Chaohui
    Li, Youming
    JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 2016, 58 (01) : 76 - 83
  • [24] Predictors of malignancies and overall mortality in Japanese patients with biopsy-proven non-alcoholic fatty liver disease
    Seko, Yuya
    Sumida, Yoshio
    Tanaka, Saiyu
    Taketani, Hiroyoshi
    Kanemasa, Kazuyuki
    Ishiba, Hiroshi
    Okajima, Akira
    Nishimura, Takeshi
    Yamaguchi, Kanji
    Moriguchi, Michihisa
    Mitsuyoshi, Hironori
    Yasui, Kohichiroh
    Minami, Masahito
    Itoh, Yoshito
    HEPATOLOGY RESEARCH, 2015, 45 (07) : 728 - 738
  • [25] Prevalence and Treatment of Arterial Hypertension Among Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease
    Schramm, C.
    Dinter, J.
    Demir, M.
    Lengerli, K.
    Toex, U.
    Steffen, H-M.
    JOURNAL FUR HYPERTONIE, 2010, 14 (04): : 21 - 25
  • [26] CIRCULATING PCSK9 LEVELS ARE CORRELATED WITH ADVANCED DISEASE IN PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE.
    Munoz-Hernandez, R.
    Gato, S.
    Rojas, A.
    Gallego-Duran, R.
    Montero-Vallejo, R.
    Beltran-Romero, L. M.
    Gil-Gomez, A.
    Maya-Miles, D.
    Ampuero-Herrojo, J.
    Romero-Gomez, M.
    ATHEROSCLEROSIS, 2021, 331 : E142 - E143
  • [27] Burden of Non-Alcoholic Fatty Liver Disease in the Veterans Administration
    Kanwal, Fasiha
    Kramer, Jennifer R.
    Kowalkowski, Marc A.
    Duan, Zhigang
    White, Donna L.
    El-Serag, Hashem
    GASTROENTEROLOGY, 2013, 144 (05) : S947 - S947
  • [28] Diagnostic performance of non-invasive liver fibrosis risk scores in biopsy-proven non-alcoholic fatty liver disease patients in India
    Manya Prasad
    Sunanda Gupta
    Nikky Kashyap
    Umesh Kapil
    Indian Journal of Gastroenterology, 2023, 42 : 192 - 198
  • [29] Diagnostic performance of non-invasive liver fibrosis risk scores in biopsy-proven non-alcoholic fatty liver disease patients in India
    Prasad, Manya
    Gupta, Sunanda
    Kashyap, Nikky
    Kapil, Umesh
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2023, 42 (02) : 192 - 198
  • [30] The comparison of resting metabolic rate between biopsy-proven non-alcoholic steatohepatitis and non-alcoholic fatty liver patients
    Kenger, Emre Batuhan
    Guveli, Hakan
    Ergun, Can
    Kaya, Eda
    Yilmaz, Yusuf
    HEPATOLOGY FORUM, 2020, 1 (01): : 14 - 19